| Carboplatin/paclitaxel | Carboplatin/gemcitabine | Carboplatin/pemetrexed | Carboplatin/ paclitaxel/bevacizumab | ||
| 106 | 35 | 25 | 28 | ||
| Age | ≥70 | 16.0% | 31.4% | 24.0% | 25.0% |
| <70 | 84.0% | 68.6% | 76.0% | 75.0% | |
| Gender | Female | 35.8% | 48.6% | 40.0% | 39.3% |
| Male | 64.2% | 51.4% | 60.0% | 60.7% | |
| Smoker | Yes | 88.3% | 91.2% | 88.0% | 71.4% |
| No | 11.7% | 8.8% | 12.0% | 28.6% | |
| Histology | Adenocarcinoma | 42.6% | 28.6% | 88.0% | 67.9% |
| SCC | 24.8% | 22.9% | 0.0% | 10.7% | |
| NSCLC NOS | 32.7% | 48.6% | 12.0% | 21.4% | |
| Differentiation | Well differentiated | 3.8% | 18.2% | 16.7% | 0.0% |
| Moderately differentiated | 26.4% | 27.3% | 25.0% | 38.5% | |
| Poorly differentiated | 69.8% | 54.5% | 58.3% | 61.5% | |